DURHAM, N.C.--(BUSINESS WIRE)--Phase Bioscience, Inc. announced today that it has successfully raised the first tranche in a Series B financing from Johnson & Johnson Development Corporation. Johnson & Johnson Development Corporation joins long-term investor Hatteras Venture Partners in supporting the growth of Phase Bioscience. “This is a significant equity investment for Phase Bioscience and will allow the company to move forward with the development of the purification and the new drug delivery technologies recently acquired from Duke University,” said Gabriel R. Cipau, PhD, Chairman and CEO of Phase Bioscience. “The company’s technology has the potential to deliver pharmaceutical products with greater efficacy and lower side effects, and make an impact on the ability to cost effectively purify therapeutic proteins and peptides.”
